Dr. Finn Discusses Research in Triple-Negative Breast Cancer

Richard S. Finn, MD
Published: Tuesday, Nov 19, 2013

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

TNBC is an area of unmet need, Finn says, and is defined by the absence of a druggable target and represents many molecular subtypes in and of itself. Research has been conducted in TNBC looking at Src inhibition and PARP inhibition.

One PARP inhibitor, BMN 673, looks particularly potent for BRCA-mutated breast cancer. Still, Finn says, there remains a need to understand the biology of TNBC.

Richard S. Finn, MD, associate professor of medicine, Department of Medicine, Division of Hematology/Oncology, Geffen School of Medicine at UCLA, discusses current research in triple-negative breast cancer (TNBC).

TNBC is an area of unmet need, Finn says, and is defined by the absence of a druggable target and represents many molecular subtypes in and of itself. Research has been conducted in TNBC looking at Src inhibition and PARP inhibition.

One PARP inhibitor, BMN 673, looks particularly potent for BRCA-mutated breast cancer. Still, Finn says, there remains a need to understand the biology of TNBC.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x